860627P

C18 Dihydroceramide (d18:0/18:0)

Avanti Polar Lipids 860627P, powder

• Synonym(s): N-stearoyl-D-erythro-sphinganine
• Empirical Formula (Hill Notation): C₃₆H₇₃NO₃
• CAS Number: 2304-80-5
• Molecular Weight: 567.97
• UNSPSC Code: 12352211

Properties

• form: powder
• packaging: pkg of 1 × 25 mg (860627P-25mg); pkg of 1 × 5 mg (860627P-5mg)
• manufacturer/tradename: Avanti Polar Lipids 860627P
• lipid type: sphingolipids
• shipped in: dry ice
• storage temp.: −20°C
• SMILES string: OC[C@]([H])(NC(CCCCCCCCCCCCCCCCC)=O)[C@]([H])(O)CCCCCCCCCCCCCCC
• InChI: 1S/C36H73NO3/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-36(40)37-34(33-38)35(39)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h34-35,38-39H,3-33H2,1-2H3,(H,37,40)/t34-,35+/m0/s1
• InChI key: KZTJQXAANJHSCE-OIDHKYIRSA-N

Description

General description

C18 Dihydroceramide (d18:0/18:0) or N-Stearoylsphinganine is a synthetic lipid. Acylation of sphinganine with stearoyl (FA-CoA with C18 acyl chain) by dihydro ceramide synthase 1, yields C18-dihydroceramide.

Application

C18 Dihydroceramide (d18:0/18:0) has been used as a standard for the quantitation of sphingolipid metabolites in adipose tissues by quadrupole time-of-flight (Q-TOF) mass spectrometry.

Biochem/physiol Actions

Dihydroceramides act as precursors for ceramides in the mammalian de-novo sphingolipid pathway. vitamin D supplementation increases plasma C18 dihydroceramide (C18-DHC) levels in type 2 diabetes mellitus (T2D) patients. Low serum concentration of C18-DHC has been observed in patients with history of graft rejection and ischemic type biliary lesions (ITBL). Therefore, it can be used as a predictor of graft rejection.

Packaging

5 mL Amber Glass Screw Cap Vial (860627P-25mg)

5 mL Amber Glass Screw Cap Vial (860627P-5mg)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Safety Information

• Storage Class Code: 11 - Combustible Solids